Baker Brothers Advisors - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2014$84,550,000
+241.3%
256,375
-29.3%
1.08%
+208.0%
Q4 2013$24,775,000
-1.1%
362,8470.0%0.35%
-2.0%
Q3 2013$25,047,000
+20.7%
362,847
-21.6%
0.36%
-13.4%
Q2 2013$20,754,000462,8470.41%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2014
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders